Steven D Schwartz1, Carl D Regillo2, Byron L Lam3, Dean Eliott4, Philip J Rosenfeld3, Ninel Z Gregori3, Jean-Pierre Hubschman5, Janet L Davis3, Gad Heilwell5, Marc Spirn2, Joseph Maguire2, Roger Gay6, Jane Bateman6, Rosaleen M Ostrick5, Debra Morris6, Matthew Vincent6, Eddy Anglade6, Lucian V Del Priore7, Robert Lanza8. 1. Jules Stein Eye Institute Retina Division, and David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: schwartz@jsei.ucla.edu. 2. Wills Eye Hospital and Thomas Jefferson University, Philadelphia, PA, USA. 3. Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA. 4. Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, MA, USA. 5. Jules Stein Eye Institute Retina Division, and David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 6. Advanced Cell Technology, Marlborough, MA, USA. 7. Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA. 8. Advanced Cell Technology, Marlborough, MA, USA. Electronic address: rlanza@advancedcell.com.
Abstract
BACKGROUND: Since they were first derived more than three decades ago, embryonic stem cells have been proposed as a source of replacement cells in regenerative medicine, but their plasticity and unlimited capacity for self-renewal raises concerns about their safety, including tumour formation ability, potential immune rejection, and the risk of differentiating into unwanted cell types. We report the medium-term to long-term safety of cells derived from human embryonic stem cells (hESC) transplanted into patients. METHODS: In the USA, two prospective phase 1/2 studies were done to assess the primary endpoints safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium in nine patients with Stargardt's macular dystrophy (age >18 years) and nine with atrophic age-related macular degeneration (age >55 years). Three dose cohorts (50,000, 100,000, and 150,000 cells) were treated for each eye disorder. Transplanted patients were followed up for a median of 22 months by use of serial systemic, ophthalmic, and imaging examinations. The studies are registered with ClinicalTrials.gov, numbers NCT01345006 (Stargardt's macular dystrophy) and NCT01344993 (age-related macular degeneration). FINDINGS: There was no evidence of adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted tissue. Adverse events were associated with vitreoretinal surgery and immunosuppression. 13 (72%) of 18 patients had patches of increasing subretinal pigmentation consistent with transplanted retinal pigment epithelium. Best-corrected visual acuity, monitored as part of the safety protocol, improved in ten eyes, improved or remained the same in seven eyes, and decreased by more than ten letters in one eye, whereas the untreated fellow eyes did not show similar improvements in visual acuity. Vision-related quality-of-life measures increased for general and peripheral vision, and near and distance activities, improving by 16-25 points 3-12 months after transplantation in patients with atrophic age-related macular degeneration and 8-20 points in patients with Stargardt's macular dystrophy. INTERPRETATION: The results of this study provide the first evidence of the medium-term to long-term safety, graft survival, and possible biological activity of pluripotent stem cell progeny in individuals with any disease. Our results suggest that hESC-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement. FUNDING: Advanced Cell Technology.
BACKGROUND: Since they were first derived more than three decades ago, embryonic stem cells have been proposed as a source of replacement cells in regenerative medicine, but their plasticity and unlimited capacity for self-renewal raises concerns about their safety, including tumour formation ability, potential immune rejection, and the risk of differentiating into unwanted cell types. We report the medium-term to long-term safety of cells derived from human embryonic stem cells (hESC) transplanted into patients. METHODS: In the USA, two prospective phase 1/2 studies were done to assess the primary endpoints safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium in nine patients with Stargardt's macular dystrophy (age >18 years) and nine with atrophic age-related macular degeneration (age >55 years). Three dose cohorts (50,000, 100,000, and 150,000 cells) were treated for each eye disorder. Transplanted patients were followed up for a median of 22 months by use of serial systemic, ophthalmic, and imaging examinations. The studies are registered with ClinicalTrials.gov, numbers NCT01345006 (Stargardt's macular dystrophy) and NCT01344993 (age-related macular degeneration). FINDINGS: There was no evidence of adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted tissue. Adverse events were associated with vitreoretinal surgery and immunosuppression. 13 (72%) of 18 patients had patches of increasing subretinal pigmentation consistent with transplanted retinal pigment epithelium. Best-corrected visual acuity, monitored as part of the safety protocol, improved in ten eyes, improved or remained the same in seven eyes, and decreased by more than ten letters in one eye, whereas the untreated fellow eyes did not show similar improvements in visual acuity. Vision-related quality-of-life measures increased for general and peripheral vision, and near and distance activities, improving by 16-25 points 3-12 months after transplantation in patients with atrophic age-related macular degeneration and 8-20 points in patients with Stargardt's macular dystrophy. INTERPRETATION: The results of this study provide the first evidence of the medium-term to long-term safety, graft survival, and possible biological activity of pluripotent stem cell progeny in individuals with any disease. Our results suggest that hESC-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement. FUNDING: Advanced Cell Technology.
Authors: I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira Journal: Neuromolecular Med Date: 2015-09-15 Impact factor: 3.843
Authors: Paul Whiting; Julie Kerby; Peter Coffey; Lyndon da Cruz; Ruth McKernan Journal: Philos Trans R Soc Lond B Biol Sci Date: 2015-10-19 Impact factor: 6.237
Authors: Julien Maruotti; Srinivas R Sripathi; Kapil Bharti; John Fuller; Karl J Wahlin; Vinod Ranganathan; Valentin M Sluch; Cynthia A Berlinicke; Janine Davis; Catherine Kim; Lijun Zhao; Jun Wan; Jiang Qian; Barbara Corneo; Sally Temple; Ramin Dubey; Bogdan Z Olenyuk; Imran Bhutto; Gerard A Lutty; Donald J Zack Journal: Proc Natl Acad Sci U S A Date: 2015-08-12 Impact factor: 11.205
Authors: Lyndon da Cruz; Kate Fynes; Odysseas Georgiadis; Julie Kerby; Yvonne H Luo; Ahmad Ahmado; Amanda Vernon; Julie T Daniels; Britta Nommiste; Shazeen M Hasan; Sakina B Gooljar; Amanda-Jayne F Carr; Anthony Vugler; Conor M Ramsden; Magda Bictash; Mike Fenster; Juliette Steer; Tricia Harbinson; Anna Wilbrey; Adnan Tufail; Gang Feng; Mark Whitlock; Anthony G Robson; Graham E Holder; Mandeep S Sagoo; Peter T Loudon; Paul Whiting; Peter J Coffey Journal: Nat Biotechnol Date: 2018-03-19 Impact factor: 54.908